Effect of Omega 3 Fatty Acids on Vascular Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01888211|
Recruitment Status : Completed
First Posted : June 27, 2013
Last Update Posted : June 27, 2013
|Condition or disease||Intervention/treatment||Phase|
|Previous Myocardial Infarction||Dietary Supplement: Omega 3 fatty acid supplementation Dietary Supplement: Olive Oil||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effect of Omega 3 Fatty Acid Supplementation on Endothelial Function, Endogenous Fibrinolysis and Platelet Activation in Patients With a Previous Myocardial Infarction|
|Study Start Date :||December 2004|
|Actual Primary Completion Date :||June 2006|
|Actual Study Completion Date :||June 2009|
Experimental: Omega 3 fatty acid supplementation
Omacor 2 grams daily
Dietary Supplement: Omega 3 fatty acid supplementation
2 grams Omacor daily
Placebo Comparator: Olive Oil
Olive Oil capsule 2 grams daily
Dietary Supplement: Olive Oil
2 grams olive oil daily
- Endogenous fibrinolysis (net release of plasma t-PA,IU mL-1) [ Time Frame: Measured at 6 weeks after omega 3 fatty acids or placebo ]Endogenous fibrinolysis was measured by drawing blood during intrabrachial substance P infusion and then plasma t-PA antigen and activity (t-PA Combi Actibind Elisa Kit; Technoclone, Vienna, Austria) concentrations were determined by enzyme-linked immunosorbent assays. Estimated net release of plasma t-PA was the product of the infused forearm plasma flow (based on the mean hematocrit and the infused forearm blood flow) and the concentration difference between the infused and noninfused arms.
- Endothelial vasomotor function (forearm blood flow, mL l00 mL-1 min-1) [ Time Frame: Measured at 6 weeks after omega 3 fatty acids or placebo ]Forearm blood flow was measured during intrabrachial infusions of acetylcholine, substance P and sodium nitroprusside by venous occlusion plethysmography with mercury-in-silicone elastomer strain gauges.
- Circulating platelet-monocyte aggregates (%). [ Time Frame: Measured at 6 weeks after omega 3 fatty acids or placebo ]Whole blood was immunolabelled with appropriate monoclonal antibodies for subsequent flow cytometric analysis of platelet-monocyte aggregation. Platelet-monocyte aggregates were defined as the percentage of monocytes positive for CD42a.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01888211
|Centre for Cardiovascular Sciences, University of Edinburgh|
|Edinburgh, Scotland, United Kingdom, EH16 4SB|
|Study Chair:||David E Newby||University of Edinburgh|
|Principal Investigator:||Jehangir N Din||University of Edinburgh|